Browse EX-10 agreements

1 EXECUTION VERSION AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this “Agreement”) by and between KLX Energy Services Holdings, Inc., a Delaware corporation (“Company”), and Christopher J. Baker (“Executive”) is entered into as of August 11, 2026 (the “Effective Date”). Executive and Company shall be referred to individually as a “Party” and collectively as the “Parties” within this Agreement. WHEREAS, effective as of July 28, 2020, Executive and Company entered into that certain Executive Employment Agreement (the “Original Employment Agreement”); WHEREAS, Company and Executive mutually desire to continue Executive’s employment with Company and to enter into this Agreement; and WHEREAS, this Agreement shall supersede and replace in its entirety the Original Employment Agreement, with the terms of Executive’s employment being set forth herein. NOW, THEREFORE, in consideration of the mutual promises, covenants, representations, obligations and agreements contained herein, and for other valuable consideration, the receipt and adequ

…

June 10, 2026

Manasi Jaiman, M.D., M.P.H.

Via email to […***…]

Re: Retention Bonus

Dear Manasi:

Aardvark Therapeutics, Inc. (the “Company”) is pleased to offer you the opportunity to receive a cash retention bonus in the aggregate amount of $357,000 (the “Retention Bonus”), on the following terms and conditions.

The Retention Bonus consists of two components: (i) the first component of the Retention Bonus ($204,000) is a guarantee of your 2026 annual bonus (the “Guaranteed Bonus Portion”), and (ii) the remaining component ($153,000) is intended solely as a retention bonus for your continued service through the Retention Date (as defined below). Your 2026 annual bonus, if any, based on the achievement of applicable goals, will be reduced (but not below zero) by the Guaranteed Bonus Portion.

…

June 10, 2026

Nelson Sun

Via email to […***…]

Re: Retention Bonus

Dear Nelson:

Aardvark Therapeutics, Inc. (the “Company”) is pleased to offer you the opportunity to receive a cash retention bonus in the aggregate amount of $346,500 (the “Retention Bonus”), on the following terms and conditions.

The Retention Bonus consists of two components: (i) the first component of the Retention Bonus ($198,000) is a guarantee of your 2026 annual bonus (the “Guaranteed Bonus Portion”), and (ii) the remaining component ($148,500) is intended solely as a retention bonus for your continued service through the Retention Date (as defined below). Your 2026 annual bonus, if any, based on the achievement of applicable goals, will be reduced (but not below zero) by the Guaranteed Bonus Portion.

…

Execution Version

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. “[***]” INDICATES THAT INFORMATION HAS BEEN REDACTED

SECOND AMENDED AND RESTATED EXHIBITOR SERVICES AGREEMENT

BETWEEN NATIONAL CINEMEDIA, LLC AND AMC (AS DEFINED HEREIN)

AMENDED AND RESTATED AS OF APRIL 17, 2025

---

FINAL

TABLE OF CONTENTS

…

FIRST AMENDMENT TO THE

AMENDED AND RESTATED CONSULTING AGREEMENT

    This First Amendment (the “Amendment”) to the Amended and Restated Consulting Agreement dated the 19th of April, 2024 (the “Agreement”) is entered and made effective as of April 17th, 2026 (the “Amendment Effective Date”), by and between Neurogene Inc., a Delaware corporation having a place of business at 535 West 24thStreet, 5thFloor, New York, NY 10011 (“Company”) and Stuart Cobb Consulting Ltd., a limited company registered at Office 8, Hardengreen Park, Eskbank, Midlothian, Scotland EH22 3NX (“Consultant”). Capitalized terms used herein but not defined herein will have the meanings ascribed to such terms in the Agreement.

WHEREAS, the parties hereto previously entered into the Agreement for the engagement of the Consultant to provide the services described therein, including causing Stuart Cobb (“Cobb”) to provide such services for a term of two (2) years from the date of the Agreement; and

…

NEW LENDER JOINDER AGREEMENT

This NEW LENDER JOINDER AGREEMENT (this “Agreement”) is entered into as of August 6, 2026, by and among FNLR OP LP, a Delaware limited partnership (the “Parent Borrower”), certain Wholly Owned Foreign Subsidiaries of the Parent Borrower party hereto (collectively with the Parent Borrower, the “Borrowers” and each individually, a “Borrower”), FORTRESS NET LEASE REIT, a Maryland statutory trust (the “Parent”), certain subsidiaries of the Parent party hereto (collectively with the Parent, the “Guarantors” and each individually, a “Guarantor”), SUMITOMO MITSUI TRUST BANK, LIMITED, NEW YORK BRANCH, a Japanese banking corporation (the “New Lender”) and acknowledged and consented to by BANK OF AMERICA, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”) and as the sole L/C Issuer under the Credit Agreement referred to below.

WITNESSETH

…

MAZE THERAPEUTICS, INC. (“Company”)

Non-Employee Director Compensation Policy

Effective January 30 2025

Amended June 1, 2026

The Company’s Board of Directors (the “Board”) believes it is in the best interests of the Company and its stockholders to adopt a compensation program for non-employee directors as set forth herein (the “Non-Employee Director Compensation Policy” or the “Policy”) to provide for an annual cash retainer and certain equity awards in consideration of each non-employee director’s service on the Board and any committees thereof. This Policy may be amended or terminated at any time in the sole discretion of the Board.

Cash Compensation

Cash compensation payable to each non-employee director shall consist of the following annual fees, which shall be paid quarterly in arrears and shall be pro-rated for partial quarters served, including for the initial quarter in which this Policy is adopted:

•

General Board Service Fee: $40,000

•

Board Chair Fee (in addition to General Board Service Fee): $30,000

•

…

BICARA THERAPEUTICS INC.
2026 INDUCEMENT PLAN

SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS

The name of the plan is the Bicara Therapeutics Inc. 2026 Inducement Plan (as amended from time to time, the “Plan”). The purpose of the Plan is to enable Bicara Therapeutics Inc. (the “Company”) and its Affiliates to grant equity awards to induce highly-qualified prospective officers and employees who are Eligible Employees to accept employment and to provide them with a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer alignment of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company or one of its Affiliates. The Company intends that the Plan be reserved for persons to whom the Company may issue securities without stockholder approval as an inducement pursuant to Rule 5635(c)(4) of the Marketplace Rules of The Nasdaq Stock Market LLC.

…

#480369v9 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (together with each attached Exhibit A (each a “Business Terms Exhibit”) and Exhibit B (the “EU Data Privacy Exhibit”), the “Agreement”), is made as of the date of last signature (the “Effective Date”) by and between Bicara Therapeutics Inc., a Delaware corporation with a principal business address at 116 Huntington Ave., Suite 703, Boston, MA 02116 (“Bicara”), and David Raben, MD with an address at 5558 S. Hillside Street Greenwood, CO 80111 (“Consultant”). Bicara desires to have the benefit of Consultant’s knowledge and experience, and Consultant desires to provide services to Bicara, all as provided in this Agreement. 1. Services. Bicara retains Consultant, and Consultant agrees to provide consulting and advisory services to Bicara as Bicara may from time-to-time reasonably request and as specified in each Business Terms Exhibit (the “Consulting Services”). Any changes to the Consulting Services (and any related compensation adjustments) must be agreed to in writing between Consultant and Bicara prior to implementation of t

…

bicara.com 116 Huntington Ave. Ste. 703 info@bicara.com Boston, MA 02116 May 7, 2026 By E-Mail David Raben 5558 S. Hillside Street Greenwood, CO 80111 Dear David: This letter confirms your separation from employment and proposes an agreement between Bicara Therapeutics Inc., its existing or future parents, subsidiaries, or affiliated corporations or entities and any division of any of them, as well as any of their successors or assigns (collectively the “Company”) and you. The Company and you are collectively referred to as the “Parties.” Your employment with the Company shall end effective May 7, 2026 (the “Separation Date”). As of the Separation Date, you will not be authorized to enter into any agreements or otherwise perform any work on behalf of the Company except as specifically requested and authorized by the Company. Specifically, during this period of time, the Company reserves the right to utilize your services to assist in the transition of your responsibilities on an as-needed basis to be determined within the Company’s sole discretion. The Company shall pay you for all t

…

Rare Earths Americas, Inc.

Executive Severance and Change in Control Plan

ARTICLE I - PURPOSE

This Executive Severance and Change in Control Plan has been established by Rare Earths Americas, Inc. (the “Company”) on August 12, 2026 (the "Effective Date") to provide Participants with the opportunity to receive severance benefits in the event of certain terminations of employment. The purpose of the Plan is to attract and retain qualified executives. The Plan is intended to be a top hat welfare benefit plan under ERISA.

Capitalized terms used but not otherwise defined herein have the meanings set forth in ARTICLE II.

ARTICLE II - DEFINITIONS

"ACA" has the meaning set forth in Section 4.01(c).

"Administrator" means the Compensation Committee.

"Applicable Severance Multiplier" means the multiplier contained in a Participant's Participation Agreement that is used to determine the amount of severance the Participant may receive if a Qualifying Termination occurs as set out in Article IV hereof.

"Benefit Continuation" has the meaning set forth in Section 4.01(c).

…

PERFORMANCE SHARE AGREEMENT UNDER THE RARE EARTHS AMERICAS, INC. 2026 EQUITY INCENTIVE PLAN

Pursuant to Rare Earths Americas, Inc.’s (the “Company”) 2026 Equity Incentive Plan (the “Plan”), the Company made the following award of performance share units to you (the “PSUs”). The grant is subject to and governed by the Plan generally, and all capitalized terms not defined herein shall have the meanings given to such terms in the Plan.

Notice of Performance Share Award

Participant ______________________________

Grant Date _____________________________

Target Number of PSUs (“Target PSUs”): ______________

Pursuant to the terms and conditions set forth below, you may earn between 0% - 100% of the Target PSUs based on the price of the Company’s shares during the Performance Period. Except as set forth below under “Special Vesting Events,” you must be in Continuous Service (as defined below) from the Grant Date through the vesting of the PSUs in order to earn any PSUs during such Performance Period.

…